Literature DB >> 2598972

Acetylator polymorphism in Parkinson's disease.

J M Ladero1, F J Jimenez, J Benitez, M J Fernandez-Gundin, C Martinez, A Llerena, J Cobaleda, J J Muñoz.   

Abstract

Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disease and in 93 age-matched normal control subjects. Sixty-nine patients and 54 control subjects were classified as slow acetylators (NS). No relation was found among acetylator polymorphism and age at onset or clinical stage of disease. Amongst slow acetylators, the percentage of acetylated sulphamethazine in plasma was significantly lower in patients than in controls. Despite this finding, the results do not support any relationship between acetylator polymorphism and the risk of developing Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2598972     DOI： 10.1007/bf00558506

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  18 in total

1.  Cimetidine and dapsone acetylation.

Authors:  J T Wright; R P Goodman; A M Bethel; C M Lambert
Journal:  Drug Metab Dispos       Date:  1984 Nov-Dec       Impact factor: 3.922

2.  [Changes in the determination of the acetylation phenotype during treatment with procainamide].

Authors:  J P Aubry; M Biour; A Cheymol; P Jaillon
Journal:  Therapie       Date:  1980 Sep-Oct       Impact factor: 2.070

3.  Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

Authors:  A Barbeau; T Cloutier; M Roy; L Plasse; S Paris; J Poirier
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

4.  [Hepatic acetylator phenotype in diabetic polyneuropathy].

Authors:  J M Ladero Quesada; A Arrojo Romero; E Cocero Oviedo; M Gómez Pérez; F Cano Iglesias; C Franco Carcedo; E Camarero González; P Sánchez Creus
Journal:  Rev Clin Esp       Date:  1983-03-31       Impact factor: 1.556

5.  N-Acetyltransferase and arylhydroxamic acid acyltransferase.

Authors:  W W Weber; C M King
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Hepatic acetylator phenotype in bladder cancer patients.

Authors:  J M Ladero; C K Kwok; C Jara; L Fernandez; A M Silmi; D Tapia; A C Uson
Journal:  Ann Clin Res       Date:  1985

8.  Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid.

Authors:  G R Sarma; S Kailasam; N G Nair; A S Narayana; S P Tripathy
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway.

Authors:  D W Schneck; J S Sprouse; R A Shiroff; J E Vary; F O DeWitt; A H Hayes
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

10.  Concepts in causality: chemically induced human urinary bladder cancer.

Authors:  G M Lower
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860
View more
  2 in total

1.  Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.

Authors:  Joshua E Muscat; Brian Pittman; Wayne Kleinman; Philip Lazarus; Steven D Stellman; John P Richie
Journal:  Biochem Pharmacol       Date:  2008-07-25       Impact factor: 5.858

2.  N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.

Authors:  Juergen Borlak; Stella Marie Reamon-Buettner
Journal:  BMC Med Genet       Date:  2006-03-29       Impact factor: 2.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.